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https://doi.org/10.1016/j.neo.2017.11.009Improving the treatment of patients with advanced metastatic cancer
is a daily challenge in clinical practice. The “renaissance” of
immuno-oncology is mainly due to the success of the immune
check-points inhibitors in prolonging the survival of metastatic cancer
patients in different tumor types [1]. Very interestingly, some long
lasting responses or even remissions have been reported [2].
Consequently, cancer immunotherapy became in the last decade,
one of the major breakthrough in cancer treatment. Although active
in monotherapy, anti-CTLA4 and anti-PD-1 monoclonal antibodies
are not able to overcome every aspect of tumor immunosuppressive
mechanisms. Several ongoing clinical trials attest that their
combination may improve their clinical efficacy. Nevertheless, their
associated autoimmune toxicities constitute a main reason of
treatment discontinuation or abandon (NCT02477826,
NCT03001882, NCT02982954 and NCT02231749) [3].
Thus, one of the main current challenge is how to improve cancer
immunotherapy efficiency, without increasing autoimmune toxic-
ities. An appropriate strategy may reside in a combinatorial approach
able to overcome the numerous immunosuppressive networks of the
tumor microenvironment (TME) [4] resulting in an “abscopal effect”,
a rare phenomenon first described in patients treated with
radiotherapy, characterized by regression of tumor outside the
radiation field [5].
The reproduction of such systemic reaction requires at least two
major steps, as described in our published model [6]. First, inducing
apoptosis of tumor cells and second, reprogramming the TME into a
TH1 polarized response through an IL-12-based immunotherapy.
One adequate translational approach would be to replace radiother-
apy by proapoptotic peptides (PAPs) that also offer the possibility of
targeting specifically the tumor through a systemic administration [7].
PAPs are sequences of amino acids that have the ability to induce
apoptosis after binding cell-surface receptors. They are composed of
two functional domains: a targeting domain designed to recognize
tumor cell surface and a pro-apoptotic domain designed to be
non-toxic outside of cells but toxic when internalized.
Here, we describe the combination of PAPs, composed of a protein
transduction domain (PTD) peptide coupled to a killer peptide(KLAK) which disrupts eukaryotic mitochondrial membranes, along
with an intratumor IL-12 based immunotherapy. This combination
induces, in our murine model, an abscopal effect able to reduce
massively the contralateral non-treated tumors (Figure 1A) and
consequently to prolong dramatically the mice-bearing tumor survival
(Figure 1B). In this report, we show that depletion of CD8+ T cells
suppresses completely the abscopal effect on distant contralateral
tumors, which in turn experience a dramatic progression (Figure 2A).
Our report shows for the first time the feasibility of inducing an
abscopal effect through a synergistic combinatorial approach
including locally administered PAPs and IL-12 based immunother-
apy. This combination generates a potent antitumor immunity that
acts as “in situ tumor vaccination” able to antagonize efficiently at
multiple levels the tumor immunosuppressive environment (Figure 3A).
The mechanisms implicate a rebalance of cytokine profile leading
to a TH1-dominant immune response, through an IL-12 induced
differentiation of naïve T cells [8,9]. Consequently, immunosup-
pressive cytokines produced by TH2 pre-existing cells are reduced
and cross presentation of dendritic cells (DCs) is enhanced by the
up-regulation of interferon gamma (IFNγ) secretion from TH1
cells. This process also decreases the prevalence of immunosup-
pressive actors like myeloid-derived suppressor cells (MDSCs) and
Figure 1. The intratumor co-administration of IL-12 and proapoptotic peptides (PAPs) generates abscopal effect that reduces massively the
contralateral tumor volume (A) andextends the lifespan (B) ofBALB/cmicebearingCT26coloncancer cells.UntreatedCT26 tumors (seededwith
3 × 105 cells) were established in 6-wk.-old female BALB/c mice, as described previously [6,9]. The different treatments were initiated when
tumor reachavolume~0.3cm3.Only tumorononesidewasco-injectedwithmouse recombinant IL-12 (R&Dsystems) (delivered at 10μg/day for
a period of 7 days) in the presence or absence of 300μg (30 μl final) of PAPs (PTD/KLAK) [6] for a period of 7 days only. After that, the contralateral
tumor (non-treated side) volume were evaluated twice weekly using a caliper. (A), contralateral tumors (non-treated side) in mice treated
concomitantly with IL-12 and PAPs were significantly smaller (Student's t-test; P b .001) than untreated tumors (treated with PBS, control) or
those treated with either IL-12 or PAPs alone. (B), mice treated concomitantly with IL-12 and PAPs survived longer than the untreated mice
(control) or those treated with IL-12 or PAPs alone, as shown by a Kaplan- Meier survival plot (n = 14 animals/group; P b .05, log-rank test). All
animals were bred and maintained according the guidelines of both the Federation of European Laboratory Animal Science Associations
(Tamworth, U.K.) and the Animal Experimental Ethics Committee (Paris, France). Animals were used at between 6 and 20 wk. of age. Animals
bearing tumors in excess of 20–25% of the body mass were killed.
Figure 2. The in vivo depletion of CD8+ T cells abolishes the abscopal effect of PAPs and IL-12 in BALB/c mice bearing CT26 colon cancer
cells. As described in Figure 1. Mice were depleted or not with H35.17.2 antibody (250 mg; obtained from American Type Culture
Collection) respectively, 4 days before co-treatment with IL-12 and PAPs and repeated one time by week during a period of 30 days. After
that, tumor volume were evaluated twice weekly using a caliper. The contralateral tumors in the depleted mice were significantly bigger
compared to non-depleted mice (Student's t-test; P b .001).
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proliferation and the cytolytic activity of NK cells and effector
CD8+ T-cells. However, without the microenvironment repro-
gramming conferred by IL-12 co-administration, the apoptotic cell
death is not by itself sufficient to allow an effective tumor
rejection. Together, all these synergistic modifications on tumor
microenvironment elicit a potent antitumor immunity leading to
the rejection of distant metastatic tumors (Figure 3B).
As a translational extension from this observation, we postulate that the
replacement of locally administered PAPs by an intravenous infusion (as
described in [7]) may result in the same abscopal effect. Such scenario will
undeniably open the door to the “democratization” of the abscopal effect
in the clinical practice, which may bring new hope for cancer patients
refractory to immune check-point blockade therapies.
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